TG Therapeutics TGTX Payments to Acquire Held-to-Maturity Securities
Payments to Acquire Held-to-Maturity Securities at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireHeldToMaturitySecurities.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's payments to acquire held-to-maturity securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is TG Therapeutics's payments to acquire held-to-maturity securities?
- TG Therapeutics (TGTX) reported payments to acquire held-to-maturity securities of $21.06M in Q1 2026.
- How has TG Therapeutics's payments to acquire held-to-maturity securities changed year-over-year?
- TG Therapeutics's payments to acquire held-to-maturity securities decreased by 77.1% year-over-year, from $92.06M to $21.06M.
- What is the long-term trend for TG Therapeutics's payments to acquire held-to-maturity securities?
- Over 3 years (2021 to 2025), TG Therapeutics's payments to acquire held-to-maturity securities has grown at a 58.8% compound annual growth rate (CAGR), from $55.53M to $222.24M.